- Global Pharma News & Resources

Growth Hormone (GH) Agonist - Pipeline Insight 2018 -

The "Growth Hormone (GH) Agonist -Pipeline Insight, 2018" drug pipelines has been added to's offering.

Growth Hormone (GH) Agonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Growth Hormone (GH) Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Growth Hormone (GH) Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Growth Hormone (GH) Agonist - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Growth Hormone (GH) Agonist Pipeline Products in Clinical Stages

6. Growth Hormone (GH) Agonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies Mentioned

  • Pfizer
  • Teva Pharmaceutical Industries
  • OPKO Health
  • Merck Serono
  • Novo Nordisk
  • Hanmi Pharmaceutical
  • HanAll Biopharma
  • JCR Pharmaceuticals
  • Savient Pharmaceuticals
  • Genexine
  • Critical Pharmaceuticals
  • Ascendis Pharma
  • Peptor

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 21-Dec-2018